Delving into the Latest Updates on Ferring, Inc. with Synapse

Overview

Tags

Urogenital Diseases

Neoplasms

Synthetic peptide

Hormone

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Hormone	1
Synthetic peptide	1

Top 5 Target	Count

FSHR(Follicle-stimulating hormone receptor)	1
GnRHR(Gonadotropin-releasing hormone receptor)	1

Urothelial carcinomas of the lower and upper urinary tract can be considered "twin diseases". Much of the current clinical decision-making surrounding Upper Tract Urothelial Carcinoma (UTUC) is extrapolated from evidence that is based on urothelial carcinoma of bladder patients.
The inner wall of the bladder is coated with a substance called glycosaminoglycan (GAG). GAG is known to form a gel-like layer on the apical cell membrane and act as a barrier against urine and pathogens in the lower urinary tract.
Currently no published research on the presence of a GAG layer in the upper urinary tract exists. However, literature suggests that the ureteral utothelium can be transduced without enhancers, and the ureteral urothelium may be intrinsically different from bladder, both by the presence or absence of a GAG-layer, by different composition/thickness of the GAG-layer.
Any functional differences between the urothelial layers in the bladder and in the upper urinary tract may affect the adeno-virus transduction, which again will have potential impact on future treatment of UTUC patients with a current unmet medical need.

Start Date01 Dec 2021

Sponsor / Collaborator

Århus Universitetshospital

[+1]

100 Clinical Results associated with Ferring, Inc.

Login to view more data

0 Patents (Medical) associated with Ferring, Inc.

Login to view more data

3

Literatures (Medical) associated with Ferring, Inc.

10 Feb 2025·Journal of the Canadian Association of Gastroenterology

A71 SUBGROUP ANALYSIS OF CANADIAN PARTICIPANTS IN PUNCH CD3-OLS: A PHASE 3 OPEN-LABEL CLINICALSTUDY TO EVALUATE THE SAFETY AND EFFICACY OF FECAL MICROBIOTA, LIVE-JSLM, IN ADULTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION

Author: Lee, C ; Jason, T ; Smyth, D ; Steiner, T S ; Kao, D ; Srivastava, S ; Guthmueller, B ; Elliott, S N ; Louie, T

AbstractBackgroundFecal microbiota, live-jslm (RBL) is the first United States (US) Food and Drug Administration-approved, single-dose, microbiota-based live biotherapeutic product to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care (SOC) antibiotics. In a prospective phase 3, open-label study (PUNCH CD3-OLS; NCT03931941) conducted in the US and Canada, RBL demonstrated a 73.8% treatment success rate at 8 weeks and a 91.0% sustained clinical response rate through 6 months.AimsTo evaluate the safety and efficacy of RBL in Canadian participants in PUNCH CD3-OLS.MethodsPUNCH CD3-OLS participants were aged ≥18 years with documented rCDI and confirmed use of SOC antibiotics. Participants with comorbidities including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and immunocompromising conditions due to disease and/or medications were permitted to enroll. A single dose of RBL was rectally administered within 24–72h of SOC antibiotic completion. The primary endpoint was the number of participants with RBL- or administration-related treatment-emergent adverse events (TEAEs). Secondary endpoints included treatment success at 8 weeks and sustained clinical response at 6 months after RBL administration.ResultsOf the 697 participants who received RBL, 117 were Canadian. Participants in Canada were mostly White (91.5%) and female (70.1%) with a mean (SD) age of 61.3 years (17.38). Twenty participants (17.1%) were hospitalized for their qualifying episode. Participants’ medical histories included IBD (unspecified, [1.7%, n=2]; Crohn’s disease, [6.0%, n=7]; ulcerative colitis, [5.1%, n=6]), IBS (6.8%, n=8), and mild-to-moderate immunocompromising conditions (7.7 %, n=9). TEAEs through 8 weeks after RBL administration were reported by 59.8% of participants; most were gastrointestinal (48.7%, n=57) and mild-to-moderate in severity. Serious TEAEs were reported by 5.1% of participants within 8 weeks of RBL administration. At 8 weeks, 75.2% of participants (88/117) had treatment success; of those, 90.9% (80/88) had a sustained clinical response at 6 months. Demographics, safety, and efficacy outcomes were similar for participants in the US.ConclusionsRBL was safe and efficacious for preventing rCDI among Canadian participants from PUNCH CD3-OLS, the largest study of a live microbiota-based therapy conducted to date.Funding AgenciesNRCFerring Pharmaceuticals

01 Dec 2020·BMC Pregnancy and ChildbirthQ3 · MEDICINE

Correction to: Inpatient versus outpatient induction of labour: a systematic review and metaanalysis

Q3 · MEDICINE

ArticleOA

Author: Khan, Maria ; Hashimi, Farahnosh ; Dong, Susan ; Chamy, Caroline ; D'Souza, Rohan

An amendment to this paper has been published and can be accessed via the original article.

01 Dec 2020·BMC Pregnancy and ChildbirthQ3 · MEDICINE

Inpatient versus outpatient induction of labour: a systematic review and meta-analysis

Q3 · MEDICINE

ReviewOA

Author: Khan, Maria ; Hashimi, Farahnosh ; Dong, Susan ; Chamy, Caroline ; D'Souza, Rohan

AbstractBackgroundAs the number of indications for labour induction continue to increase, the focus has shifted to performing these procedures in an outpatient setting. This study aims to systematically review published data from randomized controlled trials that compare outpatient with inpatient labour induction, to ascertain the role of outpatient labour induction for low-risk pregnancies.MethodsWe conducted a systematic review wherein we searched MEDLINE, EMBASE, Biosis Previews®, and International Pharmaceutical Abstracts from inception to January 2020 to identify randomized controlled trials that reported on maternal, fetal and resource-related outcomes following outpatient versus inpatient labour induction. Pooled incidences and mean differences were calculated using random-effects meta-analysis. Risk-of-bias was assessed using the Cochrane Risk of Bias tool. Subgroup analysis was conducted based on the method of induction.ResultsOf the 588 records identified, 12 publications, representing nine independent randomized controlled trials conducted in Australia, Europe and North America, were included. These reported on 2615 cases of labour induction (1320 outpatients versus 1295 inpatients). Overall, apart from a higher number of suspicious fetal heart rate tracings [RR = 1.43 (1.10, 1.86)] and a shorter mean length of hospital stay [MD = 282.48 min (160.23, 404.73) shorter] in the outpatient group, there were no differences in delivery method, adverse outcomes or resource-use between the two arms. On subgroup analysis, when comparing the use of balloon catheters in both arms, those induced as outpatients had fewer caesarean deliveries [RR = 0.52 (0.30, 0.90)], a shorter admission-to-delivery interval [MD = 370.86 min (19.19, 722.54) shorter], and a shorter induction to delivery interval [MD = 330.42 min (120.13, 540.71) shorter].ConclusionOutpatient labour induction in resource-rich settings is at least as effective and safe, in carefully selected patient populations, when compared with inpatient labour induction. Whether outpatient labour induction results in lower rates of caesarean deliveries needs to be explored further.Trial registrationThis systematic review was prospectively registered in Prospero (CRD42019118049).

100 Deals associated with Ferring, Inc.

Login to view more data

100 Translational Medicine associated with Ferring, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

2

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Follitropin delta ( FSHR )	Infertility More	Approved
Degarelix Acetate ( GnRHR )	Prostatic Cancer More	Approved
Quinagolide Hydrochloride ( D2 receptor )	Hyperprolactinemia More	Withdrawn